Aiming to slow dangerous lung inflammation to help fight bacterial infections like tuberculosis
Official title: An aberrant wound healing response drives myeloid-dependent disease exacerbation
Funded at Washington University · NIH-11436386 · Data updated 2026-11-12
A patient-facing program tests whether stopping a specific inflammatory cell (Spp1+ macrophages) from overreacting can help control tuberculosis and possibly improve outcomes in other inflammatory diseases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $466,500 |
| NIH project number | 1DP2AI201017-01 |
| Project ID | NIH-11436386 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with bacterial infections or inflammatory conditions where Spp1+ macrophages are implicated may benefit from future trials or therapies.
✕Less likely to help
At present, this is a basic science project; no specific patient treatment is guaranteed yet.
What this research studies
This project looks for ways to keep a special type of immune cell from overreacting during bacterial infections, especially tuberculosis. By using CRISPR-based screens and human data, researchers want to understand how Spp1+ macrophages form and how they worsen disease. If successful, the approach could lead to new strategies that complement vaccines and standard treatments. Participants may not directly join this study right away, but findings could inform future therapies and trials for patients with bacterial infections or inflammatory conditions.
Why it matters
Potential benefit: If successful, the research could lead to new treatments that reduce infection severity by modulating immune cells.
How similar studies have gone: Prior studies have linked Spp1+ macrophages to worse outcomes in infections and inflammatory diseases, but targeted therapies are still under development.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Kotov, Dmitri I — Washington University
- Study coordinator: Kotov, Dmitri I
Related research
Other NIH-funded projects on the same topics.
-
Immunomodulatory therapy to speed up healing after oral cavity injuries in kids
A new approach using a drug called FTY720 aims to improve healing and reduce pain after oral injuries or palate surgery in children.
-
Engineered protein materials to study wound healing and blood vessels
A researcher team at the University of New England is studying how the environment around a protein changes its behavior to better understand wound healing and blood vessel formation.
-
Understanding how healing tissue uses tiny messengers and scaffolds to repair wounds
A study to learn how cells talk to each other and how tiny vesicles and the extracellular matrix help skin wounds heal better.
-
Hormone signals and sex differences in how wounds heal
This grant explores how male- and female-specific hormones affect wound healing and scarring, with the goal of improving treatments for people who heal poorly.
-
Therapeutic extracellular vesicles to boost skin wound healing
A research grant is exploring how tiny cell messengers called extracellular vesicles can be engineered to improve skin wound repair in injury models.
-
Understanding how RNA guides wound healing and regeneration in adults
This NIH grant explores how RNA-related signals coordinate healing and tissue repair in adults who have wounds or injuries.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.